AMY BENNETT: Open Payments
NPI 1467758904 · MALVERN, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$997 in 55 payments from 17 companies in 2025. Trend: 2023 $136 · 2024 $319 · 2025 $997
Food & beverage: $997
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $233 |
| Novo Nordisk Inc | 10 | $161 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $131 |
| Dexcom, Inc. | 5 | $93 |
| PFIZER INC. | 5 | $80 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $64 |
| Lilly USA, LLC | 3 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 1 | $30 |
| Abbott Laboratories | 1 | $21 |
Products named: XIFAXAN, FARXIGA, Dexcom G6 Transmitter, Wegovy, Rybelsus, AIRSUPRA, CAPLYTA, BREZTRI.
Industry payments across AR — which companies pay providers there.
